Ideally, our study would have compared the results obtained with the glistening-free lens with those of other IOLs by means of a randomised trial. Additionally, 28.7% of the eyes included in the study presented no ocular pathology, whereas 71.3% had pathology of some form including macular degeneration, glaucoma, epiretinal membrane, diabetic retinopathy and previous vitrectomy. Some of these diseases have been associated with a greater rate of posterior capsule opacification, which may have induced some selection bias.
As mentioned previously, there is a paucity of data describing clinical outcomes following enVista IOL implantation. Nevertheless, the lens appears to compare favourably with other lenses on the market.
Previously, we undertook a 91-patient prospective study in which patients were implanted with one of three monofocal toric IOLs: the Lentis LT (Oculentis), the enVista or the AcrySof IQ (Alcon Laboratories Inc.) or a multifocal toric IOL (the AcrySof IQ ReSTOR, Alcon Laboratories Inc.).
Patients implanted with the glistening-free toric IOL achieved the best uncorrected distance visual acuity compared with the other monofocal IOLs, with 81% of eyes having 0.1 logMAR or better.15 Previous studies have demonstrated that the incidence of PCO following uncomplicated cataract surgery ranges from 50% to <5%;16-19 in the current study, only 5.3% of eyes required Nd:YAG laser posterior capsulotomy.
Overall, findings from our study clearly indicate that implantation of the glistening-free IOL leads to good visual outcomes with a low incidence of PCO. These data also highlight the effect of IOL design on vision quality.